{"filings":[{"id":94257,"accession_number":"0001683168-26-003124","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aclarion authorizes $2.5 million share repurchase program over 12 months","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $2.5M in common stock over next 12 months.","CEO Brent Ness says current valuation does not reflect full strength of Nociscan platform.","Company had $19.0M cash as of March 31, 2026; repurchase funded from existing cash.","Program may be executed via open market purchases, block trades, 10b5-1 plans, or private deals.","Management believes cash runway supports milestones including CLARITY trial initial milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106475,"accession_number":"0001683168-26-002024","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Aclarion adopts one-year stockholder rights plan with 10% trigger","event_type":"other_material","confidence":"high","bullets":["Board unanimously adopted Rights Plan effective March 19, 2026, expiring March 18, 2027.","Under the plan, one Right per share (including warrants); exercise price $14.00 per Right.","Trigger at 10% beneficial ownership; existing holders >10% grandfathered but cannot increase ownership.","Upon trigger, holders (except acquirer) can buy shares worth 2x exercise price; Board may redeem at $0.001 per Right.","Company states plan not adopted in response to any specific takeover proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106474,"accession_number":"0001683168-26-000241","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclarion closes $10.4M equity offering, reports $21.6M cash, zero debt, runway into 2028","event_type":"other_material","confidence":"high","bullets":["Closed $10.4M common-stock-only offering at $5.18/share; includes 200,000 shares and pre-funded warrants for 1.8M shares.","Cash balance $21.6M as of Jan 12, 2026; zero debt.","Cash runway extended into 2028 based on current operating plans.","Plans to accelerate CLARITY trial enrollment, launch Nociscan v2.8 in Q1'26, and pursue payer coverage.","Dawson James Securities acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106473,"accession_number":"0001683168-26-000168","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion raises ~$10.36M via registered direct offering of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["200,000 shares at $5.18 each; pre-funded warrants for 1.8M shares at $0.00001 exercise price.","Gross proceeds ~$10.36M; net to fund market development, Clarity Trial, product dev, and G&A.","Pre-funded warrants immediately exercisable with 4.99%/9.99% beneficial ownership limitation.","Closing expected Jan 9, 2026; Dawson James Securities is placement agent at 6.0% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122822,"accession_number":"0001683168-25-007516","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion raises ~$2.5M via registered direct offering of stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Issued 64,000 common shares and 236,000 pre-funded warrants at $8.36/share; gross proceeds ~$2.5M.","Pre-funded warrants have $0.00001 exercise price, exercisable immediately until fully exercised.","Proceeds to fund market development, The Clarity Trial, product development, and general corporate purposes.","Offering expected to close on October 14, 2025; placement agent fee is 7.0% of gross proceeds.","Dawson James Securities acts as exclusive placement agent for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139516,"accession_number":"0001683168-25-006659","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Aclarion appoints Greg Gould as CFO; John Lorbiecki retires","event_type":"leadership","confidence":"high","bullets":["Gregory A. Gould appointed CFO effective September 1, 2025, succeeding retiring John Lorbiecki.","Gould receives $262,500 base salary, annual bonus up to 50% of base at board discretion.","Inducement stock option for 17,000 shares at $7.15; vests 25% in one year, remainder monthly over three years.","Gould has raised over $450M in debt/equity, led 10+ acquisitions, and served as CFO at 7 public companies.","Lorbiecki will stay in a non-CFO role through October 1, 2025 to assist transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139515,"accession_number":"0001683168-25-005246","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclarion shareholders approve reverse stock split, reject equity plan amendment","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with 47,374 to 51,347 votes for; broker non-votes of 200,431.","Ratification of Haynie & Company as auditor approved: 241,005 for, 23,143 against.","Reverse stock split proposal approved: 177,593 for, 87,330 against, 2,124 abstain.","Amendment to 2022 equity incentive plan rejected: 29,621 for, 35,466 against, 1,527 abstain, with 200,431 broker non-votes.","Annual meeting was adjourned from July 7, 2025, and reconvened on July 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139514,"accession_number":"0001683168-25-004952","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Aclarion adjourns annual meeting to July 21 to solicit additional votes","event_type":"other","confidence":"high","bullets":["Annual meeting convened then adjourned without business on July 7, 2025.","Reconvened Monday, July 21, 2025 at 9:30 a.m. MT at 8181 Arista Place, Broomfield CO.","Adjournment to solicit more votes on proposals in May 13 proxy statement.","Record date remains May 9, 2025; prior proxies carry forward unless revoked.","Stockholders urged to vote by 11:59 p.m. MT July 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157085,"accession_number":"0001683168-25-004669","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO John Lorbiecki to retire; replacement search underway, expected by Q3 2025","event_type":"leadership","confidence":"high","bullets":["John Lorbiecki notified retirement on June 16, 2025; will stay to transition duties.","Company initiated search for new CFO; expects appointment before end of Q3 2025.","Lorbiecki joined as CFO in October 2021, prior to April 2022 IPO.","Retirement not due to any disagreement on controls, financials, or audit matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}